H35.3112

🧬 ICD-10-CM H35.3112 — Nonexudative AMD, Right Eye, Intermediate Dry Stage

Billable Code Confirmed

H35.3112 is a valid, billable 7-character ICD-10-CM code for FY2025. All seven characters are present: H35 (category) + .3 (degeneration of macula) + 1 (nonexudative) + 1 (right eye) + 2 (intermediate dry stage). No additional characters required — this code is complete and will process on a claim.

Non-Billable Parent Codes — Do Not Submit These

The following codes in the H35.3112 family tree are non-billable headers and will reject on a claim:

• ❌ H35.311 — 6-character — missing staging character
• ❌ H35.31 — 5-character — missing laterality AND staging Always submit H35.3112 (all 7 characters) for intermediate dry AMD, right eye.

---

🔍 Code Description

ICD-10 CM H35.3112 classifies nonexudative (dry) age-related macular degeneration of the right eye at the intermediate dry stage — a clinically significant escalation from early AMD defined by the presence of large drusen (≥125μm) and/or AMD-associated pigmentary abnormalities (RPE hyperpigmentation or hypopigmentation) at the macula of the right eye, without choroidal neovascularization or geographic atrophy involving the foveal area.^1,2

Intermediate dry AMD represents the highest-risk stage at which proven preventive intervention — AREDS2 supplementation — can meaningfully slow disease progression. Patients at this stage carry approximately an 18% five-year risk of progressing to advanced AMD (geographic atrophy or neovascular conversion) in at least one eye, making accurate staging, AREDS2 documentation, and accelerated monitoring (every 6 months) the clinical priorities.³ This is the stage most commonly encountered in the retina clinic and the one where both coding accuracy and clinical management decisions carry the highest immediate consequence.²

---

🌳 Code Tree / Hierarchy

H35.3 Degeneration of Macula and Posterior Pole  
│  
├── H35.31 Nonexudative AMD ❌ Non-billable header  
│ │  
│ └── H35.311 Right Eye ❌ Non-billable header  
│ │  
│ ├── H35.3110 Right eye, stage unspecified ⚠️ last resort  
│ ├── H35.3111 Right eye, early dry stage  
│ ├── H35.3112 Right eye, INTERMEDIATE DRY stage ◀ THIS CODE ✅  
│ ├── H35.3113 Right eye, advanced atrophic, w/o subfoveal  
│ └── H35.3114 Right eye, advanced atrophic, w/ subfoveal

The "AND/OR" Rule — Intermediate Stage Has Two Entry Points

Unlike early AMD which requires BOTH medium drusen AND no pigment changes, intermediate AMD is reached when EITHER of the following is present:

1. Large drusen (≥125μm) — regardless of whether pigmentary changes are present
2. AMD-associated pigmentary abnormality — regardless of whether drusen have reached ≥125μm

This means a patient with medium drusen (75μm) who develops new focal RPE hyperpigmentation has already crossed into intermediate AMD (H35.3112) even though drusen size alone would still suggest early. Conversely, a patient with large drusen (130μm) and no pigment changes at all is also H35.3112. Query the record carefully for both findings — either one triggers the stage upgrade from H35.3111 to H35.3112.

---

📊 Intermediate Dry AMD — Clinical Staging Criteria

Beckman Clinical Classification — Full Stage Table^2,3

Stage	ICD-10-CM Code (Right Eye)	Drusen Criteria	Pigmentary Changes	AREDS2?	Typical VA
Normal aging	No code	Small drupelets <63μm only	None	❌	20/20
Early AMD	H35.3111	Medium ≥63-<125μm	❌ None	❌	20/20-20/40
Intermediate AMD	H35.3112	≥125μm AND/OR medium + pigment	May be present	✅ YES	20/25-20/80
Advanced (no subfoveal GA)	H35.3113	Geographic atrophy, fovea spared	Present	✅ (continue)	Variable
Advanced (subfoveal GA)	H35.3114	GA involving foveal center	Present	✅ (continue)	20/200+
Wet AMD (conversion)	H35.3211	CNV — active	Present	❌ (anti-VEGF now)	Rapid drop

AREDS Simplified Severity Scale at Intermediate Stage³

AREDS Score	5-Year Risk of Advanced AMD	Stage Correlation
0	~0.5%	Normal / very early
1	~3%	Transitional early/intermediate
2	~12%	Intermediate — large drusen one eye
3	~25%	Intermediate — large drusen both eyes or GA one eye
4	~50%	Advanced — both eyes significantly affected

AREDS Score ≥2 = Intermediate AMD = H35.3112

The AREDS Simplified Severity Scale assigns 1 point per eye for: (1) presence of large drusen (≥125μm) and (2) AMD-associated pigmentary abnormality. A score of 2 or higher in either eye corresponds to intermediate AMD — the threshold at which AREDS2 supplementation becomes clinically indicated. When the ophthalmologist documents an AREDS score, use it to validate or query the staging — an AREDS score of 2+ should map to H35.3112 or higher, never H35.3111.

---

✅ Includes

The following clinical terms map to H35.3112 — right eye, intermediate dry stage:¹

• Nonexudative AMD, right eye, intermediate dry stage
• Intermediate dry AMD, right eye (Beckman classification)
• Large drusen (≥125μm), right eye, with or without pigmentary abnormalities
• Medium drusen with AMD-associated RPE hyperpigmentation or hypopigmentation, right eye
• Intermediate age-related maculopathy (ARM), right eye
• AMD, intermediate, right eye — no CNV, no geographic atrophy at foveal center

Pigmentary Change — What Qualifies?

Not all RPE pigment changes are AMD-associated. For the purposes of staging to H35.3112, the relevant pigmentary findings are:

• RPE hyperpigmentation — focal dark areas overlying or adjacent to drusen (RPE hyperplasia or migration)
• RPE hypopigmentation — focal depigmentation without frank atrophy (distinct from geographic atrophy)
• Pseudodrusen (subretinal drusenoid deposits / SDD) — soft, pale deposits internal to the RPE; increasingly recognized as carrying a particularly high risk of rapid progression and CNV conversion; often co-occurs with intermediate AMD

Do NOT include: Diabetic macular pigmentary changes, post-laser scarring, histoplasmosis scarring, or myopic macular degeneration pigment clumping — these have distinct etiologies and are NOT AMD pigmentary changes.

---

❌ Excludes

Excludes 2 — Assign Diabetic Code Instead When DM Is the Etiology¹

Code Range	Description	Action
E08.311-E08.359	Drug/chemical-induced DM with diabetic retinopathy	Use diabetic retinopathy code — NOT H35.3112
E10.311-E10.359	Type 1 DM with diabetic retinopathy	Use diabetic retinopathy code — NOT H35.3112
E11.311-E11.359	Type 2 DM with diabetic retinopathy	Use diabetic retinopathy code — NOT H35.3112
E13.311-E13.359	Other specified DM with diabetic retinopathy	Use diabetic retinopathy code — NOT H35.3112

Diabetic Patient with Both AMD and DR — Dual Coding

A diabetic patient can have both intermediate dry AMD (H35.3112) and diabetic retinopathy as simultaneously documented, separately established conditions in the same right eye. Under Excludes 2 logic, both codes are assignable when the physician explicitly documents both diagnoses as separately present. AMD and diabetic maculopathy have different pathophysiologic mechanisms, different drusen morphology, and different treatment approaches — they can coexist. Dual coding requires explicit physician differentiation; do not assume it without documentation.

---

📋 Clinical Overview

Pathophysiology at the Intermediate Stage

At the intermediate stage, the RPE stress that began with drusen accumulation in early AMD has progressed to measurable RPE dysfunction. Large drusen (≥125μm) represent significantly greater lipid-protein debris burden, with more extensive disruption of Bruch’s membrane and the choroidal-RPE oxygen exchange interface. The RPE cells overlying and adjacent to large drusen show early signs of metabolic failure — manifesting clinically as pigmentary abnormalities (hyperpigmentation from RPE hyperplasia/migration attempting repair, hypopigmentation from early focal RPE loss).²

Critically, rod photoreceptor dysfunction becomes measurable at this stage through dark adaptation testing — rods require RPE-mediated vitamin A recycling, and as RPE function degrades, rod recovery after light bleach is delayed. This functional deficit (rod intercept time >6.5 minutes) can precede structural drusen changes by up to three years and is now recognized as both an early biomarker for AMD onset and a progression monitor at the intermediate stage. The FDA-cleared AdaptDx Pro (MacuLogix) dark adaptation device measures rod intercept time and is gaining clinical adoption, though AAO guidelines as of 2024 do not yet recommend it for routine AMD management — it remains an emerging tool.

Key Clinical Differences vs. Early Stage (H35.3111)

Feature	Early (H35.3111)	Intermediate (H35.3112)
Drusen size	≥63-<125μm	≥125μm (large)
Pigmentary changes	None	May be present (triggers stage regardless of drusen size)
AREDS2 indicated?	❌ Not indicated	✅ Indicated — start now
Monitoring frequency	Annual	Every 6 months
CNV conversion risk	~1-3% per year	~3-7% per year (higher with SDD present)
Typical VA	20/20	20/25-20/80 (variable)
Dark adaptation	Mildly delayed	Measurably delayed (RIT >6.5 min common)
Home monitoring	Amsler grid	Amsler grid + home OCT emerging
Symptoms	Asymptomatic mostly	Mild metamorphopsia, night vision complaints, contrast reduction

AREDS2 Supplementation — Intermediate Stage Is the Threshold³

AREDS2 IS Indicated at H35.3112 — Recommend and Document Every Visit

The AREDS2 formulation is the standard of care for intermediate dry AMD and must be recommended and documented at every H35.3112 encounter. The AREDS2 trial demonstrated a ~25% reduction in risk of progression to advanced AMD over 5 years in patients with intermediate AMD or advanced AMD in one eye.

Component	Daily Dose	Role
Vitamin C	500mg	Antioxidant — reduces oxidative stress to RPE
Vitamin E	400 IU	Antioxidant — membrane stabilization
Lutein	10mg	Macular pigment precursor — replaces beta-carotene
Zeaxanthin	2mg	Macular pigment precursor
Zinc	80mg	Cofactor for antioxidant enzymes
Copper	2mg	Prevents zinc-induced copper deficiency anemia

No Beta-Carotene in Current AREDS2 Formula

The original AREDS formula included beta-carotene, which was found to significantly increase lung cancer risk in current and former smokers. The AREDS2 reformulation eliminated beta-carotene and replaced it with lutein/zeaxanthin, which proved equally effective without the lung cancer risk. Never recommend a beta-carotene-containing supplement for a smoker with AMD — confirm the patient is taking the AREDS2 formula, not the original AREDS formula.

New 2025 data note: Recent analysis suggests AREDS2 supplements may also slow the spread of geographic atrophy toward the fovea by approximately 55% when atrophy begins at the periphery of the macula — extending the clinical value of AREDS2 beyond preventing conversion, potentially protecting foveal function even in advanced stages. [web:94]

Emerging: Dark Adaptation Testing at Intermediate Stage

Dark adaptation testing measures rod intercept time (RIT) — how long (in minutes) it takes for rod photoreceptors to recover sensitivity after bright light exposure. A RIT >6.5 minutes is considered abnormal and has been validated as a biomarker for AMD, detectable up to 3 years before structural drusen changes appear on imaging. [web:91][web:98]

Dark Adaptation Finding	RIT	Clinical Interpretation
Normal	≤6.5 minutes	No rod dysfunction
Subclinical AMD	>6.5 min, no drusen	Earliest functional AMD signal — new classification [web:91]
Early AMD	>6.5 min, medium drusen	Rod dysfunction correlates with drusen burden
Intermediate AMD	Significantly prolonged	Rod dysfunction measurable; progression marker
Advanced AMD	May not recover within 45 min	Severe RPE and photoreceptor loss [web:98]

CPT Coding for Dark Adaptation Testing

Dark adaptation testing (AdaptDx Pro) is billed under 92284 — Dark adaptation examination with interpretation and report. Coverage under H35.3112 varies by payer — Medicare local coverage policies are evolving. Check the applicable LCD before billing. The AAO’s 2024 guidelines recommend against routine dark adaptation testing for AMD management outside of clinical research, though the clinical evidence is building rapidly. [web:95] This is an emerging area worth monitoring for your CIC study — expect guideline updates.

Emerging: Home OCT Monitoring for Intermediate AMD

Home OCT (telemedicine-based optical coherence tomography) is gaining traction for intermediate AMD patients as a surveillance tool for early detection of wet AMD conversion between clinic visits. [web:96] Systems like the Notal OCT Analyzer (approved by FDA) allow patients to perform OCT scans at home and transmit results to their retina specialist. This is particularly valuable at the intermediate stage where conversion risk is meaningful — detecting new subretinal fluid before VA drops significantly can enable earlier anti-VEGF treatment initiation and better visual outcomes. Coding and billing implications are evolving — monitor CMS coverage updates for remote monitoring CPT codes in this space.

---

💰 HCC Risk Adjustment (CMS-HCC v28)

Field	Detail
CMS-HCC Model Version	v28 (2024-2025 Implementation)
HCC Assignment	❌ Not Mapped
HCC Category	N/A
RAF Coefficient	0.000
RxHCC Assignment	Not Mapped

H35.3112 carries no direct HCC weight under CMS-HCC v28. [web:70]

High-Risk Population — Maximize Comorbidity Capture

Intermediate AMD patients are among the highest-risk Medicare beneficiaries for visual disability progression. At the H35.3112 encounter, systematically review for and ensure complete coding of all qualifying comorbidities:

Common Comorbidity	HCC (v28)	Action
Type 2 DM (any complication)	HCC 18	Highest priority — extremely common co-occurrence
Coronary artery disease	HCC 85	Document manifestation
Heart failure	HCC 85	Document type and severity
Atrial fibrillation	HCC 96	Especially relevant (anticoagulation risk if wet AMD conversion)
CKD Stage 3-5	HCC 137	Common in this age group
Morbid obesity	HCC 48	AMD progression risk factor
COPD	HCC 111	Smoking history connection

The ophthalmology visit may be one of the only physician visits for some elderly patients — make every encounter count for RAF capture.

---

🏥 MS-DRG Assignment

MDC 02 — Diseases and Disorders of the Eye (if principal — uncommon for intermediate AMD)

DRG	Title	Est. Relative Weight*
DRG 124	Other Disorders of the Eye with MCC	~0.95-1.15
DRG 125	Other Disorders of the Eye with CC	~0.70-0.90
DRG 126	Other Disorders of the Eye without CC/MCC	~0.50-0.70

*Approximate. Verify against IPPS FY2025 Final Rule tables.⁴

Vision Impairment as a CC Driver

At the intermediate stage, VA of 20/40-20/80 is common. When documented, H54.11x (blindness/low vision, right eye) may be assignable and could qualify as a CC, driving the encounter to DRG 125 rather than DRG 126. Capture vision impairment when documented — it both accurately represents the clinical burden and supports appropriate DRG tier.

---

🔗 Related ICD-10-CM Codes

Nonexudative AMD — Stage Ladder

Code	Description	Drusen	Pigment?	AREDS2?
H35.3110	Right eye, stage unspecified ⚠️	Unknown	Unknown	Query
H35.3111	Right eye, early dry	≥63-<125μm	❌	❌
H35.3112	Right eye, intermediate dry ← This Code	≥125μm or +pigment	May be	✅
H35.3113	Right eye, advanced, no subfoveal GA	GA, no foveal center	✅	✅ continue
H35.3114	Right eye, advanced, subfoveal GA	GA at foveal center	✅	✅ continue

Bilateral Intermediate AMD — Use Bilateral Code When Both Eyes Same Stage

Code	Description	Use When
H35.3132	Nonexudative AMD, bilateral, intermediate dry stage	Both eyes confirmed intermediate at same stage — prefer over separate codes
H35.3112 + H35.3121	Right intermediate + left early	Asymmetric — right further advanced than left
H35.3112 + H35.3122	Right intermediate + left intermediate	Both intermediate — use H35.3132 bilateral instead

Conversion Watch

Code	Description	Trigger
H35.3113/H35.3114	Advanced atrophic AMD, right eye	New geographic atrophy documented on fundus exam or FAF
H35.3211	Exudative AMD, right eye, active CNV	New subretinal fluid, CNV on angiography/OCT-A, vision drop, metamorphopsia

H35.3112 to H35.3211 — The Most Critical Code Transition in AMD

Conversion from intermediate dry AMD (H35.3112) to wet AMD (H35.3211) is the most clinically urgent and coding-significant transition in the H35.3 family. This conversion:

• Ends AREDS2 as the primary treatment — anti-VEGF injections begin immediately
• Changes monitoring from every 6 months to monthly initially
• Dramatically alters the claim complexity — intravitreal injections (67028-RT) + angiography + OCT begin appearing on claims
• Requires immediate code retirement of H35.3112 for the right eye — use H35.3211 from this point forward

If you see a claim where H35.3112 is still being coded for the right eye but 67028-RT (intravitreal injection, right eye) is also billed, that is a red flag for a staging code error — anti-VEGF injections are not indicated for dry AMD at any stage. Query immediately.

Associated Codes — Commonly Coded Alongside

Code	Description	Relationship
Z82.1	Family history of blindness and visual loss	Risk factor — supports medical necessity for accelerated monitoring
F17.210	Nicotine dependence, cigarettes	Active smoking — most significant modifiable risk factor; counsel and document every visit
Z87.891	Personal history of nicotine dependence	Former smoker — document; beta-carotene avoidance still relevant
H53.131	Sudden visual loss, right eye	If acute VA drop at visit — potential CNV conversion trigger
H54.11x	Blindness/low vision, right eye	If VA is ≤20/200 or low vision category — separately codeable
H35.3122	Nonexudative AMD, left eye, intermediate	Frequently bilateral — if same stage, use H35.3132 instead
Z96.1	Presence of intraocular lens	Common in this age group — cataract surgery history; relevant to VA assessment

---

🛠️ Commonly Associated CPT Codes (Ophthalmology)

Standard Monitoring Protocol for H35.3112 — Every 6 Months

Monitoring Frequency Doubles at Intermediate Stage

Intermediate AMD requires every-6-month monitoring, compared to annual monitoring for early AMD. This directly affects claim frequency and medical necessity documentation. Payers should not flag appropriately billed 6-month follow-up visits for H35.3112 — but documentation must clearly reflect the intermediate staging, AREDS2 recommendation, and clinical rationale for accelerated monitoring. If a payer queries frequency, point to the AREDS2 study protocol and the ~18% 5-year advanced AMD conversion risk that justifies biannual surveillance.

CPT Code	Description	H35.3112 Application	Frequency
92004	Ophthalmological exam, new patient	Initial intermediate AMD evaluation	Once (new patient)
92014	Ophthalmological exam, established patient	6-month AMD monitoring	Every 6 months
92250	Fundus photography with interpretation	Drusen size/density, pigment change documentation, longitudinal comparison	Every 6 months
92134	OCT posterior segment	Drusen volume, RPE integrity, new subretinal fluid detection — primary surveillance tool; supported by CMS LCD for H35.3112	Every 6 months
92235	Fluorescein angiography	Indicated when CNV conversion is suspected — new symptoms, VA drop, subretinal fluid on OCT	As needed
92240	ICG angiography	Polypoidal choroidal vasculopathy (PCV) exclusion; type 1 CNV detection when FA negative but suspicion remains	As needed
92284	Dark adaptation examination	Emerging — rod intercept time measurement (AdaptDx); check payer LCD for coverage under H35.3112	As clinically indicated
92083	Visual field examination	Central scotoma assessment when VA reduced; paracentral field for early GA detection	As clinically indicated

NCCI and Billing Considerations

Anti-VEGF Injections (67028) Are NOT Indicated for H35.3112

67028 (intravitreal injection) is indicated for wet AMD (H35.3211 and family), geographic atrophy (H35.3113/H35.3114) with Syfovre/Izervay, and other diagnoses. It is not clinically indicated for intermediate dry AMD alone. A claim pairing H35.3112 with 67028-RT should immediately trigger a query:

• Has wet AMD conversion been documented but the diagnosis code not updated?
• Is the injection being given for a different diagnosis (e.g., concurrent BRVO, CME)?
• Is there a coding error on the claim?

Resolve the discrepancy before claim submission — this pairing is an active payer edit trigger and a potential audit flag.

92235 (FA) Same DOS as 92134 (OCT) — NCCI Awareness

When fluorescein angiography (92235) is performed on the same day as OCT (92134) — typically at an intermediate AMD visit where CNV conversion is being ruled out — verify the current NCCI PTP edit status for this pair. Both are separately billable when separately medically necessary and documented, but the NCCI status should be confirmed for the applicable fiscal year before submitting together.

---

🔬 ICD-10-PCS Crosswalk (Inpatient)

Inpatient Procedures for Intermediate Dry AMD Are Rare

As with early dry AMD, there are no standard inpatient surgical procedures for intermediate dry AMD. Management is outpatient-based (monitoring, AREDS2, dark adaptation testing). In the rare inpatient scenario where a patient with H35.3112 undergoes a procedure for a concurrent retinal condition (e.g., cataract extraction for visually significant cataract affecting AMD monitoring), the PCS code reflects the procedure performed — not the AMD diagnosis. H35.3112 would serve as an additional diagnosis only.

---

💊 Coding Scenarios and Examples

---

Scenario 1 — New Diagnosis: Stage Upgraded from Early to Intermediate (Outpatient)

Clinical Vignette: A 73-year-old female returns for her annual AMD follow-up. She was coded as H35.3111 (early dry, right eye) at her last visit 12 months ago. Today’s exam reveals new large drusen (>125μm) in the right eye — several drusen have coalesced since last year. Left eye continues to show only medium drusen without pigment changes. No subretinal fluid or CNV on OCT. VA: 20/25 OD, 20/20 OS. Impression: Intermediate dry AMD, right eye (progressed from early). Early dry AMD, left eye (stable). AREDS2 supplementation initiated. 6-month follow-up scheduled.

CPT Codes:

• 92014 — Comprehensive ophthalmological exam, established patient
• 92134 — OCT posterior segment (bilateral; progression assessment and CNV exclusion)
• 92250 — Fundus photography (bilateral; progression documentation — key for staging upgrade justification)

ICD-10-CM:

• H35.3112 — Nonexudative AMD, right eye, intermediate dry stage (progressed from H35.3111 — new large drusen confirmed; AREDS2 initiated)
• H35.3121 — Nonexudative AMD, left eye, early dry stage (stable — asymmetric staging → separate codes, not bilateral)

Document the Stage Upgrade Explicitly

When AMD progresses from early to intermediate, the physician’s documentation must reflect this change — “progressed from early AMD” or “stage upgraded to intermediate” based on today’s findings. This documentation:

• Supports the code change from H35.3111 to H35.3112
• Justifies the change from annual to 6-month monitoring
• Documents the initiation of AREDS2 supplementation
• Creates a clear, auditable longitudinal staging record

A claim where the prior visit used H35.3111 and this visit uses H35.3112 without documentation of the progression reason may trigger a payer medical record request. The OCT and fundus photography reports (showing the new large drusen) provide the objective evidence.

---

Scenario 2 — Intermediate AMD Both Eyes, Symmetric — Bilateral Code (Outpatient)

Clinical Vignette: An 80-year-old male presents for AMD monitoring. OCT and fundoscopy confirm bilateral large drusen (≥125μm) with bilateral focal RPE hyperpigmentation at the posterior pole. No subretinal fluid. No geographic atrophy. VA: 20/30 OU. Already on AREDS2. Impression: Intermediate dry AMD, bilateral.

CPT Codes:

• 92014 — Comprehensive ophthalmological exam, established patient
• 92134 — OCT posterior segment (bilateral)
• 92250 — Fundus photography (bilateral)

ICD-10-CM:

• H35.3132 — Nonexudative AMD, bilateral, intermediate dry stage (both eyes same stage → bilateral code preferred)

Use Bilateral Code H35.3132 — Not Two Separate Codes

When both eyes are confirmed at the same intermediate dry stage, the bilateral code H35.3132 is more efficient and accurate than coding H35.3112 + H35.3122 separately. The bilateral code correctly represents the bilateral nature of the disease. Reserve separate laterality codes for when the two eyes are at different stages.

---

Scenario 3 — AREDS2 Non-Compliance Discovered at Visit (Outpatient — CDI Opportunity)

Clinical Vignette: A 76-year-old female with known intermediate dry AMD, right eye, presents for 6-month monitoring visit. Review of systems reveals she stopped taking her AREDS2 supplements 4 months ago due to GI upset. OCT shows stable drusen, no new fluid. VA: 20/30 OD. Physician counsels patient on importance of AREDS2 compliance and recommends switching to a different AREDS2 formulation with softgel coating for better GI tolerance.

CPT Codes:

• 92014 — Comprehensive ophthalmological exam, established patient (extended counseling supports 99XXX level — if extended counseling dominates and is separately documented, E/M level selection applies)
• 92134 — OCT posterior segment
• 92250 — Fundus photography

ICD-10-CM:

• H35.3112 — Nonexudative AMD, right eye, intermediate dry stage (unchanged)
• Z91.19 — Patient’s noncompliance with other medical treatment (AREDS2 non-compliance is a clinically relevant documentation finding — code it)

Code AREDS2 Non-Compliance — It's Clinically Relevant

When a patient with intermediate AMD (H35.3112) is documented as non-compliant with AREDS2 supplementation, assign Z91.19 (Patient’s noncompliance with other medical treatment) as an additional code. This documents a clinically significant gap in preventive management, supports the E/M counseling time if applicable to level selection, and builds a complete clinical picture in the coding record.

---

Scenario 4 — Intermediate AMD with Suspected CNV Conversion — Urgent Evaluation (Outpatient)

Clinical Vignette: A 78-year-old male with known intermediate dry AMD, right eye (H35.3112), calls in reporting sudden new distortion in the right eye when checking his Amsler grid this morning. Urgently seen same day. VA: 20/40 OD (from 20/25 at last visit 3 months ago). OCT reveals new subretinal fluid in the right eye. Fluorescein angiography confirms active choroidal neovascularization (CNV), right eye. Diagnosis changed to wet AMD, right eye, active CNV. Intravitreal bevacizumab injection, right eye, administered.

CPT Codes:

• 92014 — Comprehensive ophthalmological exam, established patient (modifier -25 — significant E/M separate from injection)
• 92134 — OCT posterior segment (new subretinal fluid identified — critical finding)
• 92235 — Fluorescein angiography (CNV confirmation — separate medical necessity)
• 67028-RT — Intravitreal injection, right eye (bevacizumab)

ICD-10-CM:

• H35.3211 — Exudative AMD, right eye, with active choroidal neovascularization (converted — retire H35.3112 for right eye immediately)
• H35.3122 — Nonexudative AMD, left eye, intermediate dry stage (if left eye was intermediate — still dry, unchanged)

Stop Using H35.3112 for the Right Eye — Immediately and Permanently

Once wet AMD conversion is documented, H35.3112 is retired for the right eye forever (unless there is a future documented involution of the CNV with a return to purely dry AMD — extremely rare). From this encounter forward:

• Right eye → H35.3211 (active CNV) or H35.3213 (inactive CNV) depending on treatment response
• Left eye → continues with appropriate dry AMD stage code
• Monitoring shifts from every 6 months to monthly initially, then extending per treatment response
• Treatment shifts from AREDS2 supplementation to monthly anti-VEGF injections

The Amsler grid alarm system worked exactly as intended in this scenario — document the patient’s use of home monitoring and the symptom timeline in the record. It directly supports medical necessity for the urgent same-day evaluation and imaging.

---

Scenario 5 — Intermediate AMD as Additional Diagnosis, Inpatient CABG

Clinical Vignette: A 77-year-old male is admitted for coronary artery bypass grafting (CABG). H&P documents: CAD, hypertension, type 2 DM, and “intermediate age-related macular degeneration, bilateral, being followed by retina.” The AMD does not directly affect surgical planning but is an active, documented chronic condition.

Principal Diagnosis:

• I25.10 — Atherosclerotic heart disease of native coronary artery without angina pectoris (drives admission — MDC 05)

Additional Diagnoses:

• H35.3132 — Nonexudative AMD, bilateral, intermediate dry stage (documented active chronic condition — bilateral intermediate per H&P)
• E11.9 — Type 2 DM without complications
• I10 — Essential hypertension

MS-DRG Assignment:

• Groups to MDC 05 (Circulatory System) — NOT MDC 02

UHDDS Criteria Met — Code the AMD

“Intermediate AMD, bilateral” documented in the H&P problem list and actively followed by a specialist meets UHDDS criteria for additional diagnosis coding. While it doesn’t affect the surgical care directly, it:

• Accurately reflects the patient’s comorbidity burden
• Supports AREDS2 medication reconciliation documentation during the admission
• Is relevant to nursing care planning (visual limitations affect self-care ability)
• Contributes to the completeness of the discharge record for post-acute care providers

---

⚠️ Coding Pitfalls and Tips

	Pitfall or Tip
❌	Never submit H35.311 (6-character) — always use H35.3112 (all 7 characters)
❌	Do not code H35.3112 when only medium drusen with NO pigment changes are present — that is H35.3111 (early); intermediate requires large drusen OR pigmentary changes
❌	Do not continue using H35.3112 after wet AMD conversion — switch to H35.3211 immediately and permanently for that eye
❌	Do not bill 67028 alongside H35.3112 without a separate diagnosis justifying the injection — anti-VEGF is not indicated for dry AMD; this pairing triggers payer queries
❌	Do not use the bilateral code H35.3132 when eyes are at different stages — use separate laterality codes when stages differ
❌	Do not recommend or document beta-carotene in AREDS2 counseling for smokers — use lutein/zeaxanthin formulation only
✅	AREDS2 must be documented and recommended at every H35.3112 visit — it is the standard of care; document the conversation even if the patient is already compliant
✅	Monitor every 6 months — document the rationale in the plan; this is the standard cadence for intermediate AMD and supports the visit frequency if payer questions arise
✅	Use H35.3132 (bilateral) when both eyes are intermediate at the same stage — more accurate and efficient than two separate laterality codes
✅	Code AREDS2 non-compliance (Z91.19) when documented — clinically relevant and supports E/M counseling level
✅	Code vision impairment (H54.11x) when VA is reduced to low-vision or legal blindness range — serves as a CC for DRG tier
✅	Counsel Amsler grid use at every visit and document it — the grid is the primary home monitoring tool for detecting CNV conversion between office visits; new distortion = urgent same-day evaluation
✅	At every intermediate AMD encounter, sweep for HCC comorbidities — DM, CAD, CKD, A-fib — these are extremely common in this population and carry significant RAF weight
✅	Watch for pseudodrusen (SDD) documentation — when documented alongside H35.3112, they signal significantly higher CNV conversion risk; note in CDI and consider querying for more frequent monitoring documentation

---

📚 Sources

1. CMS/NCHS. ICD-10-CM Official Guidelines for Coding and Reporting, FY2025; Tabular List — H35.31 Nonexudative AMD, 7th character staging instructions; H35 Excludes 2 notation; General Coding Guidelines Section I.B — Laterality; Section I.B.13 — Coding for Bilateral Conditions.

2. Ferris FL, Wilkinson CP, Bird A, et al. “Clinical Classification of Age-related Macular Degeneration.” Ophthalmology. 2013;120(4):844-851. (Beckman Initiative for Macular Research Classification Committee — large drusen and pigmentary change criteria for intermediate AMD.) [web:86]

3. AREDS2 Research Group. “Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration.” JAMA. 2013;309(19):2005-2015. AREDS2 formulation, 25% risk reduction in intermediate AMD to advanced AMD progression.

4. CMS. IPPS Final Rule FY2025 — MS-DRG Definitions Manual v42. MDC 02 — Diseases and Disorders of the Eye, DRGs 124-126.

5. Optometric Management. “The Good News About AMD Prevention and Early Intervention.” March 2026. Dark adaptation testing (AdaptDx), rod intercept time, subclinical AMD classification, and intermediate AMD monitoring updates. [web:91]

6. Jackson GR, et al. “The Science of Rod-Mediated Dark Adaptation, an Outcome Measure for AMD Clinical Trials.” PMC. Published March 2026. ALSTAR2 study — RMDA as functional biomarker for intermediate AMD progression. [web:98]

7. Retina Today. “Diagnostic Strategies for Early Diagnosis and Monitoring.” March 2025 Supplement. Home OCT telemedicine systems for intermediate AMD CNV conversion detection. [web:96]

8. Aetna. “Age-Related Macular Degeneration — Medical Clinical Policy Bulletin.” 2024 update. AAO guideline note — dark adaptation not yet recommended for routine AMD management as of 2024. [web:95]

9. CMS. Local Coverage Article: Billing and Coding: Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI). Article A56916; revised 2024. H35.3112 confirmed as covered diagnosis for 92134.

10. CMS. 2024 Medicare Advantage Risk Adjustment — CMS-HCC Model v28 ICD-10-CM Mappings. Baltimore, MD: Centers for Medicare & Medicaid Services. H35.3112 confirmed not mapped.

11. icd10coded.com. “H35.3112 ICD-10 Code — Nonexudative age-related macular degeneration, right eye, intermediate dry stage.” Confirmed billable FY2025. [web:90]